<DOC>
	<DOCNO>NCT01435018</DOCNO>
	<brief_summary>This study do compare safety efficacy three combination treatment Kaposi 's Sarcoma AIDS .</brief_summary>
	<brief_title>Three Chemo Regimens Adjunct ART Treatment Advanced AIDS-KS</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>Inclusion Criteria Step 1 : HIV1 infection Biopsy diagnostic KS time prior study entry . Current KS stage T1 use ACTG criterion . A minimum five indicator KS cutaneous marker lesion plus additional two lesion great equal 4x4 mm accessible punch biopsy . CD4+ lymphocyte cell count obtain within 28 day prior study entry DAIDSapproved laboratory . Certain laboratory value , define protocol , obtain within 14 day prior study entry . Cardiac ejection fraction great equal 50 % obtain within 14 day prior study entry . Female study volunteer reproductive potential must negative serum urine pregnancy test sensitivity least 50 mIU/mL perform within 24 hour initiate protocolspecified medication . All participant must agree participate conception process ( active attempt become pregnant impregnate , donate sperm , vitro fertilization ) . If participate sexual activity could lead pregnancy , participant must agree two reliable form contraceptive use simultaneously receive protocolspecified medication , 6 week stop medication . Study volunteer reproductive potential ( woman postmenopausal least 24 consecutive month undergone hysterectomy and/or bilateral oophorectomy men document azoospermia ) eligible without require use contraceptive . Ability swallow oral medication adequate venous access . Karnofsky performance status ≥ 60 within 28 day prior entry . Ability willingness participant legal guardian/representative provide inform consent . Exclusion Criteria Step 1 : Current chronic , acute , recurrent serious infection participant complete least 14 day therapy prior Step 2 entry and/or clinically stable . Serious illness require systemic treatment and/or hospitalization within 14 day prior entry . Current history know pulmonary fibrosis , chronic obstructive pulmonary disease ( COPD ) , emphysema , bronchiectasis , diffuse significant local radiographic interstitial infiltrates chest xray ( CXR ) compute axial tomography ( CAT ) . Oxygen saturation le 90 % and/or exercise desaturation great 4 % within 14 day prior study enrollment . Grade ≥3 peripheral neuropathy ( PN ) entry . Breastfeeding . Receipt ART 28 day immediately prior entry . Prior current systemic locally administer chemotherapy . Prior current radiation therapy . Prior current immunotherapy , e.g. , interferon alfa . Corticosteroid use dos give replacement therapy adrenal insufficiency within last 30 day prior study entry . Any immunomodulator , HIV vaccine , live attenuate vaccine , investigational therapy investigational vaccine within 30 day prior study entry . Known allergy/sensitivity hypersensitivity component study drug formulation . Active drug alcohol use dependence would interfere adherence study requirement . Current anticipate receipt prohibit medication list section 5.5.2 protocol . In opinion investigator , psychological social condition , addictive disorder would preclude compliance protocol . New York Heart Association Functional Class IIIV heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>